Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
  • G01N2333/475—Assays involving growth factors
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
  • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
  • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/90—Enzymes; Proenzymes
  • G01N2333/914—Hydrolases (3)
  • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
  • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
  • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
  • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
  • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
  • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
  • G01N2333/96486—Metalloendopeptidases (3.4.24)
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2800/00—Detection or diagnosis of diseases
  • G01N2800/36—Gynecology or obstetrics
  • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Definitions

• the technology described herein relates to methods of detecting or predicting preeclampsia (PE).
• the technology described herein also relates to commercial packages, . such as diagnostic kits, for performing a method of detecting or predicting PE.
• PE preeclampsia
• PE is defined according to the guidelines of the International Society for the Study of Hypertension in Pregnancy (Davey et al, Am. J. Obstet Gynecol; 158: 892-98, 1988) as gestational hypertension with proteinuria (for previously normotensive women) or severe PE as severe gestational hypertension with proteinuria (for women with chronic hypertension). For women with chronic hypertension, superimposed PE is defined by the new development of proteinuria. Gestational hypertension is defined as two recordings of diastolic blood pressure of 90 mm Hg or higher at least 4 h apart, and severe pressure of 110 mm Hg or higher at least 4 h apart or one recording of diastolic blood pressure of at least 120 mm Hg.
• Proteinuria is defined as excretion of 300 mg or more protein in 24 h or two readings of 2+ or higher on dipstick analysis of midstream or catheter urine specimens if no 24 h collection was available. Women are classified as previously normotensive or with chronic hypertension before 20 weeks' gestation. Thus, detection of PE is predominantly carried out using measurement of blood pressure and testing for proteinuria in pregnant women. These procedures and the care of affected women and of the premature children make considerable demands on healthcare resources. Accurate identification of women at risk could dramatically reduce costs of antenatal care.
• More accurate and robust identification of women at risk would target those women most likely to benefit from these prophylactic therapies. Those identified at lower risk could be provided with less intensive and less expensive antenatal care. In addition accurate prediction of those women at risk of PE would enable streaming of healthcare resources to those most at risk, and result in a large saving in health care costs through reduction of antenatal visits for those at low risk.
• PLGF placenta growth factor
• VEGF vascular endothelial growth factor
• PAI-l/PAI-2 ratio has previously been published (Chappell et al, 1999, Lancet, 354, 810-816) and others have documented raised PAI-l/PAI-2 in established PE (Rath et al, 1993, British Journal of Obstetrics and Gynaecology, KX), 370-4) and elevated PAI-I in women who subsequently developed PE (Halligan et al, 1994, British Journal of Obstetrics and Gynaecology, 101, 488-92). PLGF has been shown to be reduced in women with established PE (Torry et al, 1998, American Journal of Obstetrics and Gynaecology, .
• Leptin has been found to increase with gestation in normal pregnant women (Highman et al, 1998, American Journal of Obstetrics and Gynaecology, 178, 1010-5). Leptin has also been shown to rise even further in established PE, the first report being published by Mise et al, Journal of Endocrinology and Metabolism, 83, 3225-9, 1998. Furthermore, Anim-Nyame et al, Hum.
• a method of predicting pre-eclampsia involves determining in a maternal sample obtained from a subject the level of soluble tissue necrosis factor alpha receptor 1 (sTNF ⁇ Rl) and Matrix Metalloproteinase-9 (MMP-9).
• a method of predicting PE involves determining in a maternal sample obtained from a subject the level of sTNF ⁇ Rl and placental growth factor (PLGF).
• a method for predicting PE using one or more biochemical markers can additionally includes measuring one or more haemodynamic variables.
• the haemodynamic variable can be any parameter or abnormality associated with PE.
• the haemodynamic variable can be any parameter or abnormality of a uterine artery waveform obtained from the subject, such as diastolic notch or an abnormal resistance index (for example, an abnormal resistance index (Rl) or pulsatility index (Pl)).
• the haemodynamic variable can be blood pressure, such as systolic blood pressure (SBP), diastolic blood pressure (DBP), or mean arterial pressure (MAP, defined as DBP + (SBP-DBP)/3).
• SBP systolic blood pressure
• DBP diastolic blood pressure
• MAP mean arterial pressure
• the blood pressure of the subject can be determined using any known technique allowing accurate determination of the subject's blood pressure. By additionally determining the blood pressure of the subject, the specificity and sensitivity of the method is further improved.
• the blood pressure of the subject can be determined from reviewing or analysing blood pressure data obtained from the subject.
• a method for predicting PE as described herein can additionally include determining the presence of diastolic notch in a uterine artery waveform obtained from the subject. By additionally determining the presence of diastolic notch, the specificity and sensitivity of the method can be further improved.
• the uterine artery waveform can be obtained by any suitable method, for example, by Doppler Ultrasound.
• Placenta growth factor failed to show the pronounced rise normally observed in healthy pregnancies.
• PAI-2 was also found to be reduced in such women.
• the levels of leptin, PAI-I and ICAM were found to be raised in such women.
• the methods for predicting PE described herein can additionally include determining in a maternal sample obtained from a subject the level of one or more additional markers, for example, one or more of total PLGF, leptin, plasminogen activator inhibitor-1 (PAI-I) , sTNF ⁇ Rl. MMP-9 and intercellular adhesion molecule-1 (ICAM). It has been found that one or more of these additional markers are useful for improving the specificity and sensitivity of the method.
• a method in which levels of sTNF ⁇ Rl and MMP-9 are determined can additionally include determining the level of plasminogen activator inhibitor-2 (PAI-2) in the maternal sample. By additionally determining the presence of PAI-2, the specificity and sensitivity of the method can be further improved. Additional specific examples of marker combinations are described herein below.
• PAI-2 plasminogen activator inhibitor-2
• the technology described herein provides a method for predicting PE that includes determining in a maternal sample obtained from a subject the level of soluble tissue necrosis factor alpha receptor 1 (sTNF ⁇ Rl) and Matrix Metalloproteinase-9 (MMP-9), and determining the presence of a diastolic notch in a uterine artery waveform obtained from the subject, wherein a positive prediction is given by high sTNF ⁇ Rl, low MMP-9 and the presence of a diastolic notch.
• sTNF ⁇ Rl soluble tissue necrosis factor alpha receptor 1
• MMP-9 Matrix Metalloproteinase-9
• Another method provided by the technology includes determining in a maternal sample obtained from a subject the level of soluble tissue necrosis factor alpha receptor 1 (sTNF ⁇ Rl), and placenta growth factor (PLGF), wherein a positive prediction is given by high sTNF ⁇ Rl, and low PLGF. If desired, the method can further include determining the presence of a diastolic notch in a uterine artery waveform obtained from the subject, wherein a positive prediction is given by high sTNF ⁇ Rl, and low PLGF and the presence of a diastolic notch.
• sTNF ⁇ Rl soluble tissue necrosis factor alpha receptor 1
• PLGF placenta growth factor
• the technology provides a method for predicting PE that includes determining in a maternal sample obtained from a subject the level of soluble tissue necrosis factor alpha receptor 1 (sTNF ⁇ Rl), Matrix Metalloproteinase-9 (MMP-9) and PLGF, wherein a positive prediction is given by high sTNF ⁇ Rl, low MMP-9 and low PLGF.
• sTNF ⁇ Rl soluble tissue necrosis factor alpha receptor 1
• MMP-9 Matrix Metalloproteinase-9
• PLGF a positive prediction is given by high sTNF ⁇ Rl, low MMP-9 and low PLGF.
• Also provided is a method for predicting PE that includes determining in a maternal sample obtained from a subject the level of soluble tissue necrosis factor alpha receptor 1 (sTNF ⁇ Rl), Matrix Metalloproteinase-9 (MMP-9) and plasminogen activation inhibitor-2 (PAI-2), wherein a positive prediction is given by high sTNF ⁇ Rl, low MMP-9 and low PAI-2.
• sTNF ⁇ Rl soluble tissue necrosis factor alpha receptor 1
• MMP-9 Matrix Metalloproteinase-9
• PAI-2 plasminogen activation inhibitor-2
• a method for predicting PE includes determining in a maternal sample obtained from a subject the level of soluble tissue necrosis factor alpha receptor 1 (sTNF ⁇ Rl) and Matrix Metalloproteinase-9 (MMP-9), and determining the subject's systolic blood pressure (SBP), wherein a positive prediction is given by high sTNF ⁇ Rl, low MMP-9 and high SBP.
• SBP systolic blood pressure
• the method can involve determining the subject's mean arterial pressure (MAP), wherein a positive prediction is given by high sTNF ⁇ Rl, low MMP-9 and high MAP.
• MAP mean arterial pressure
• the technology described herein provides a method for predicting PE that includes determining in a maternal sample obtained from a subject the level of soluble tissue necrosis factor alpha receptor 1 (sTNF ⁇ Rl), Matrix Metalloproteinase-9 (MMP-9) and another marker.
• the other marker can be leptin, wherein a positive
• the marker can be total PLGF, wherein a positive prediction is given by high sTNF ⁇ Rl, low MMP-9 and low total PLGF.
• the marker can be plasminogen activation inhibitor-1 (PAI-I), wherein a positive prediction is given by high sTNF ⁇ Rl, low MMP-9 and high PAI-I.
• PAI-I plasminogen activation inhibitor-1
• the marker can be ICAM, wherein a positive prediction is given by high sTNF ⁇ Rl, low MMP-9 and high ICAM.
• the term "predicting" when used in reference to pre-eclampsia means determining a likelihood, risk or assessment of a possibility for development of preeclampsia in an individual during pregnancy.
• the term includes detecting early PE.
• a maternal sample taken from a pregnant woman can be any sample from which it is possible to measure the markers mentioned above.
• the sample can be blood.
• Other exemplary types of samples include serum, other blood fractions and urine.
• Levels of biomarkers also can be determined in maternal cells, for example, cells collected from a bodily fluid or a tissue sample such a cytrophoblast and syncytiotrophoblast cells.
• Maternal samples can be taken at any time from about 10 weeks gestation.
• the sample can be taken at between 12 and 38 weeks gestation or between 20 and 36 weeks.
• the maternal sample may be taken during one or more of the following times: 11-14 weeks gestation; 15-17 weeks gestation; 19-21 weeks gestation; and 23-35 weeks gestation.
• Soluble tissue necrosis factor alpha receptor 1 is a standard term well known to those skilled in the art.
• sequence of the human form of sTNFoRl is given in the NCBI Protein database under accession no. GL339750, version AAA61201.1. See also Fuchs et ah, Genomics, 13, 219-224, 1992.
• sTNFoRl Soluble tissue necrosis factor alpha receptor 1
• Matrix Metalloproteinase-9 (MMP-9) is a standard term well known to those skilled in the art.
• the sequence of the human form of MMP-9 is given in the NCBI Protein database under accession no. GI: 74272287, version NP_004985.2.
• MMP-9 There are numerous ways of detecting MMP-9 including the commercially available Oncogene Research ProductsTM MMP-9 ELISA.
• Placenta growth factor is a standard term used in the art and refers to the free form found in the individual unless indicated otherwise.
• the amino acid sequence of human PLGF is known (see NCBI Protein database, accession no. XP 040405, +. GL20149543, version NPJ302623.2).
• There are numerous methods of detecting PLGF including the commercially available Quantikine Human PLGF immunoassay from R&D Systems Inc.
• Free PLGF refers to PLGF that is not in a complex with any other protein.
• the bound form of PLGF refers to PLGF that is a complex with one or more proteins, e.g., Fltl.
• Plasminogen activator inhibitor-2 (PAI-2) is a standard term used in the art and is clear to those skilled in the art.
• the sequence of the human form of PAI-2 is given in the NCBI Protein database under accession no. GI: 1567409, version CAA02099.1.
• There are numerous methods of detecting PAI-2 including the commercially available Tint Elize PAI-2 kit from Biopool International.
• Plasminogen activator inhibitor- 1 is a standard term used in the art and is clear to those skilled in the art.
• sequence of the human form of PAI-I is given in the NCBI Protein database under accession no. GI: 189542, version AAA60003.1. See also Ginsburg et al, J. Clin. Invest., 78, 1673-1680, 1986.
• There are numerous methods of detecting PAI-I including the commercially available Tint Elize PAI-I kit from Biopool International.
• Leptin is a standard term used in the art and is clear to those skilled in the art.
• sequence of the human form of leptin is given in the NCBI Protein database under accession no. GL66474463, version AAY46797.1.
• methods of detecting leptin including Auto Delfia assays.
• Intercellular adhesion molecule 1 is a standard term used in the art and is clear to those skilled in the art.
• sequence of the human form of ICAM in two isoforms is given in the NCBI Protein database under accession no. GL33340673, version AAQ14901.1 and accession no. GL33340675, version AAQ14902.1.
• There are numerous methods of detecting ICAM including Auto Delfia assays.
• Diastolic notch is a standard term well known to those skilled in the art. In particular, the term refers to the dip in the early diastolic phase of the uterine artery wave form which has been associated with later abnormal outcome of pregnancy including preeclampsia (Chien et al., BJOG., 2000, 107(2), 196-208). Diastolic notch can be persistent in the uterine artery Doppler waveform of pregnant women at risk of several different abnormal pregnancy outcomes. The presence of the diastolic notch alone is not indicative of PE.
• the uterine artery waveform can be measured using Doppler ultrasound.
• Doppler ultrasound to measure the uterine artery waveform is well known to those skilled in the art (Chien et al. BJOG. 2000; 107 (2): 196-208).
• the uterine artery waveform can be measured at any time from about 10 weeks gestation.
• the measurement can be taken from 12 weeks gestation or between 20 and 25 weeks.
• the blood pressure of the subject such as systolic blood pressure (SBP), diastolic blood pressure (DBP), or mean arterial pressure (MAP, defined as DBP + (SBP-DBP)/3
• SBP systolic blood pressure
• DBP diastolic blood pressure
• MAP mean arterial pressure
• SBP-DBP mean arterial pressure
• the normal level of the relevant population of pregnant women is typically determined.
• the relevant population can be defined based on, for example, ethnic background or any other characteristic that can affect normal levels of the markers.
• the relevant population for establishing the normal level of the markers is, for example, selected on the basis of low risk for PE (i.e. no known risk marker for PE, such as previous PE, diabetes, prior hypertension etc.).
• the measured levels can be compared and the significance of the difference determined using standard statistical methods. If there is a substantial difference between the measured level and the normal level (i.e. a statistically significant difference), then there is a clinically important risk that the individual from whom the levels have been measured will develop PE. This risk can be quantified and expressed as a percentage by the use of likelihood ratios.
• a risk determination can include determining the standard deviation score for each marker and measurement (except the presence or absence of a diastolic notch), based on the distribution of the values observed in healthy pregnant women of the same gestation who do not go on to develop PE.
• the determination can additionally include combining the standard deviation scores into a single combined predictor, based either on logistic regression or on multivariate modelling of the normal distribution, or on some other appropriate statistical method.
• the Z-scores derived from the markers as described in appendix 2
• the level of sensitivity and specificity can be altered by altering the level at which a subject is considered to be at risk of PE. In some situations, e.g., when screening large numbers of women at low risk of PE, it is important to have high specificity. In other situations, it can be important to have a balance between high sensitivity and specificity, e.g., when considering individual women at high risk of PE a balance between high sensitivity and specificity is needed.
• the method described above can be performed in conjunction with other tests for diagnostic indicators, such as levels of uric acid, etc.
• the method can also be used in order to monitor the efficiency of a prophylactic treatment for preventing the development of PE, wherein a reduction in the risk of developing PE will be indicative of the prophylactic treatment working.
• biochemical markers More than twenty biochemical markers have been shown previously to be associated with established PE and there would be no logical prior reason for choosing the specific combination of markers and measurements disclosed herein in any prospective longitudinal study for assessment of use as predictive indicators.
• a commercial package such as a research or diagnostic kit for performing a method described herein.
• a kit can include reagents useful for determining the level of the markers selecting for detecting or predicting PE. Suitable agents for assaying for the markers include antibodies and other target binding molecules, enzyme linked immunoassay reagents, RIA reagents and reagents for Western blotting.
• the kit can also include apparatus for measuring the uterine artery waveform, for example, a Doppler Ultrasound apparatus.
• the kit can also include apparatus for measuring the blood pressure of the subject
• the kit can also include a computer programmed with an algorithm for calculating the subject's risk of developing PE 3 instructions and other items useful for performing a method described herein.
• pre-eclampsia related disorders or syndromes include, for example, pregnancy induced hypertension, HELLP syndrome, intrauterine growth retardation and superimposed gestosis.
• risk factors for PE chronic hypertension, diabetes, previous PE, chronic renal disease, antiphospholipid syndrome, Body Mass Index >30 in first pregnancies, abnormal uterine artery Doppler waveform. 172 were available for analysis; the remainder were not included
• Blood samples were taken at 11-14 weeks gestation, and then at 15-17, 19-21 and 23- 35 weeks. After delivery the 19 cases of pre-eclampsia were matched 1:2 to high risk controls, and 1 :2 with standard risk controls for biochemical markers. Blood markers and the results of Doppler ultrasound (diastolic notch; resistance index (RI); pulsatility index (PI)), alone and in combination were considered at 12, 16, 20 and 24 weeks.
• the biomarkers measured were: free PLGF, bound PLGF, total PLGF, soluble FIt-I, Leptin, PAI-I, PAI-2, MMP-9, ICAM and soluble TNF-alpha Rl (sTNF ⁇ Rl).
• sTNF ⁇ Rl All of these other than sTNF ⁇ Rl were measured using Auto Delfia assays developed for this purpose.
• sTNF ⁇ Rl was measured using a commercially available ELISA assay (R&D Systems). Resistance index and presence of diastolic notch were derived from the uterine artery Doppler waveform.
• Gestational-adjusted likelihood-ratio scores were created by establishing reference ranges in both cases and controls for the 13 indicators in both cases and controls (free
• PLGF PLGF, bound PLGF, total PLGF, MMP-9, Leptin, PAI-I, PAI-2, sFlt-1, sTNF ⁇ Rl , ICAM, pulsatility index (PI), diastolic notch and resistance index (RI)).
• Bound PLGF was found to add nothing to the predictive power of free and total PLGF and was removed from further consideration. Soluble Fit was also excluded, as there were technical problems with the assay. For comparison, the combinations of markers considered in International Patent Application WO 02/37120 are also shown.
• Receiver Operating Characteristic (ROC) areas are shown together with Sensitivity, and positive predictive values (PPV) for critical values chosen to give 5%, 10%, 15% false positive rates (FPR), equivalent to 95%, 90% and 85% specificity.
• FPR false positive rates
• AU these terms are familiar to those well versed in medical statistics, and are explained in standard textbooks on the subject, for example Douglas Airman "Practical Statistics in Medical Research” Chapman & Hall, London (1991) pp 409-419.
• PPV is the probability of a woman becoming a case, given a positive test result. It can be calculated as (Prevalence*Sensitivity)/(Prevalence*sensitivity + (l-prevalence)*(l-Specificity)). For the purposes of these calculations, 5% Prevalence is assumed in low risk women, 15% in high risk women.
• MMP-9, PLGF and soluble sTNF ⁇ Rl are selected for further work, optionally with one or more of diastolic notch, blood pressure (SBP or MAP), PAI-I, PAI-2, leptin and ICAM.
• SBP or MAP blood pressure
• PAI-I PAI-2
• leptin ICAM
• ICAM ICAM-like CAM
• the detection rate (DR) in high risk women using the biochemical markers alone is 56%, giving a positive predictive value of 66%.
• Including the systolic blood pressure raises the DR to 84% and the PPV to 75%.
• the same combination gives 80% DR and 46% PPV.
• the methods described herein are capable of identifying at least 4 in 5 women likely to go on to develop pre-eclampsia if correctly used at a cost of only 1 false alarm in 20 women tested. By itself this could reduce the number of antenatal visits needed by most women, and focus attention on those women most at risk.
• Leptin/Free PLGF log e (Free PLGF) - 3*(PAI1:PAI2), PAI 1: PAI 2 ratio, PAI2*Free PLGF (International Patent Application WO 02/37120) are included for comparison, as are the markers soluble FLT, MMP-2, Inhibin, VEGF and Adiponectin. Low values of soluble FLT, MMP-2, VEGF and Adiponectin are analysed as though predictive of PE.
• Free PLGF 0.50 (0.28 to 0.73) 0.09 0.24 0.16 0.22 0.22 0.20 sTNF ⁇ Rl 0.80 (0.64 to 0.97) 0.35 0.55 0.48 0.46 0.58 0.40
• PAI2 0.49 (0.24 to 0.74) 0.15 0.34 0.21 0.27 0.26 0.23
• PAI l PAI 2 ratio
• MMP-2 0.62 (0.40 to 0.85) 0.20 0.17 0.28 0.13 0.34 0.11
• VEGF 0.50 (0.26 to 0.74) 0.10 0.09 0.16 0.08 0.21 0.07
• Adiponectin 0.56 (0.3 l to 0.82) 0.25 0.21 0.31 0.14 0.35 0.11
• Free PLGF 0.66 (0.47 to 0.85) 0.30 0.52 0.39 0.41 0.45 0.34 sTNF ⁇ Rl 0.71 (0.51 to 0.91) 0.23 0.45 0.34 0.38 0.43 0.34
• PAI 2 0.63 (0.39 to 0.87) 0.37 0.57 0.44 0.43 0.48 0.36
• MMP-2 0.48 (0.24 to 0.72) 0.13 0.12 0.19 0.09 0.24 0.08 Inhibin 0.46 (0.23 to 0.68) 0.14 0.13 0.20 0.10 0.25 0.08 VEGF 0.66 (0.45 to 0.87) 0.18 0.16 0.28 0.13 0.35 0.11 Adiponectiti 0.58 (0.32 to 0.85) 0.26 0.21 0.32 0.14 0.37 0.11
• Visit 3 19-21 weeks i gestation
• Free PLGF 0.75 (0.59 to 0.91) 0.43 0.60 0.51 0.47 0.56 0.40 sTNF ⁇ Rl 0.71 (0.52 to 0.90) 0.24 0.46 0.33 0.37 0.40 0.32
• PAI2 0.63 (0.42 to 0.83) 0.31 0.52 0.38 0.40 0.43 0.34
• PAI l PAI 2 j ratio
• MMP-2 0.58 (0.38 to 0.77) 0.21 0.18 0.28 0.13 0.34 0.11
• VEGF 0.68 (0.50 to 0.86) 0.18 0.16 0.28 0.13 0.36 0.11
• PAI 2 0.69 (0.49 to 0.88) 0.45 0.62 0.51 0.47 0.55 0.39
• ICAM 0.80 (0.65 to 0.96) 0.36 0.28 0.49 0.21 0.58 0.17 PI 0.84 (0.71 to 0.97) 0.62 0.69 0.66 0.54 0.69 0.45
• Soluble FLT 0.49 (0.26 to 0.71) 0.14 0.13 0.18 0.09 0.21 0.07 MMP-2 0.59 (0.39 to 0.78) 0.16 0.14 0.24 0.11 0.30 0.10 Inhibin 0.53 (0.32 to 0.75) 0.27 0.22 0.33 0.15 0.38 0.12
• VEGF 0.66 (0.48 to 0.84) 0.24 0.20 0.32 0.15 0.39 0.12 Adiponectin 0.65 (0.42 to 0.87) 0.35 0.27 0.42 0.18 0.46 0.14
• Free PLGF 0.70 (0.61 to 0.79) 0.48 0.63 0.53 0.63 0.56 0.40 sTNF ⁇ Pvl 0.74 (0.65 to 0.83) 0.25 0.47 0.37 0.47 0.45 0.35
• PAI2 0.62 (0.51 to 0.73) 0.35 0.55 0.41 0.55 0.46 0.35
• PAI l PAI 2 i ratio
• VEGF 0.55 (0.30 to 0.79) 0.08 0.21 0.15 0.21 0.21 0.20
• PAI l PAI 2 ratio
• MMP-2 0.53 (0.29 to 0.78) 0.13 0.32 0.20 0.32 0.26 0.23
• Visit 2 15-17 weeks j gestation
• Free PLGF 0.63 (0.43 to 0.83) 0.14 0.34 0.24 0.34 0.32 0.27 sTNF ⁇ Rl 0.73 (0.52 to 0.94) 0.22 0.44 0.34 0.44 0.43 0.34
• PAI l PAI 2 ratio
• VEGF 0.59 (0.38 to 0.81) 0.16 0.37 0.24 0.37 0.31 0.27
• PAI l PAI 2 ratio
• VEGF 0.60 (0.40 to 0.79) 0.18 0.39 0.25 0.39 0.30 0.26
• AdiponectinO.58 (0.38 to 0.78) 0.13 0.31 0.20 0.31 0.26 0.24
• PAI l PAI 2 ratio
• VEGF 0.57 (0.39 to 0.75) 0.11 0.29 0.18 0.29 0.24 0.22
• AdiponectinO.62 (0.42 to 0.82) 0.08 0.22 0.15 0.22 0.22 0.21 AU
• PAI l PAI 2 ratio
• MMP-2 0.53 (0.43 to 0.63) 0.03 0.10 0.07 0.10 0.12 0.13
• VEGF 0.57 (0.47 to 0.67) 0.12 0.30 0.19 0.30 0.25 0.23
• the mean values at each gestation is estimated by a quadratic curve (not shown); the coefficient of variation (and hence the standard deviation) by a linear function •
• a Z-score standard deviations score
• Plots are established (not shown) that show the standard risk women with reference lines at 3%, 50%, 97%, representing -2, 0, 2 SD above or below the mean.
• the transformations given remove the effect of gestation in standard risk women on both the mean and spread of the values. These are used to standardise the values in high risk controls and PE cases.
• the ratios PAI2/PAI1 and Leptin (pg/mL) / Free PLGF (pg/mL) are used, to keep ratios > 1. 3 subjects with PAI2 ⁇ 2*PAI1 excluded from estimates of PAIl, PAI2, and all combinations involving these.
• GEE Generalised Estimating Equations
• SE Standard Errors
• Graphs are shown with error bars based on SE. Significance tests are carried out based on both the GEE model and a random effects Tobit regression (censored at -2 and +2).
• the GEE approach gives equal weight to each woman (rather than each blood sample), and allows for repeated measurements, and corrects the Standard Errors.
• Visit 4 0.026 1.066 -0.055 0.845 -0. 511 1 .158 0. 102 0.167
• the chosen Z-scores (calculated as described in appendix 1) are each multiplied by a fixed parameter, and summed, with a further constant added.
• z_freeplgf Z(Free PLGF) z_mmp9: Z(MMP-9) z_stnfrl: Z(sTNF ⁇ Rl) z_pai2: Z(PAI-2) z_sbp: Z(SBP) notch: add only if arterial notch is present on Doppler ultrasound scan z_map: Z(MAP) z_leptin: Z(Leptin) z_totalplgf_sr: Z(Total PLGF) zjail: Z(PAI-I) z_sicam: Z(icam)

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Immunology (AREA)
• Urology & Nephrology (AREA)
• Hematology (AREA)
• Biomedical Technology (AREA)
• Chemical & Material Sciences (AREA)
• Cell Biology (AREA)
• Physics & Mathematics (AREA)
• General Health & Medical Sciences (AREA)
• Microbiology (AREA)
• Pathology (AREA)
• General Physics & Mathematics (AREA)
• Biotechnology (AREA)
• Food Science & Technology (AREA)
• Medicinal Chemistry (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Analytical Chemistry (AREA)
• Biochemistry (AREA)
• Reproductive Health (AREA)
• Gynecology & Obstetrics (AREA)
• Pregnancy & Childbirth (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Ultra Sonic Daignosis Equipment (AREA)
• Mold Materials And Core Materials (AREA)
• Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
• Adhesives Or Adhesive Processes (AREA)
• Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
• Holo Graphy (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=35998177

Family Applications (1)

Country Status (10)

Cited By (2)

Families Citing this family (14)

Citations (1)

Family Cites Families (5)

• 2006
  • 2006-01-17 GB GBGB0600916.1A patent/GB0600916D0/en not_active Ceased
• 2007
  • 2007-01-16 US US11/623,480 patent/US7638287B2/en not_active Expired - Fee Related
  • 2007-01-17 WO PCT/GB2007/000123 patent/WO2007083099A1/en not_active Ceased
  • 2007-01-17 AU AU2007206756A patent/AU2007206756B2/en active Active
  • 2007-01-17 EP EP07700392A patent/EP1974220B1/en active Active
  • 2007-01-17 CA CA2602681A patent/CA2602681C/en active Active
  • 2007-01-17 DE DE602007013524T patent/DE602007013524D1/de active Active
  • 2007-01-17 ES ES07700392T patent/ES2364314T3/es active Active
  • 2007-01-17 AT AT07700392T patent/ATE504002T1/de not_active IP Right Cessation
  • 2007-01-17 JP JP2008549934A patent/JP2009524014A/ja active Pending

Patent Citations (1)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events